User: Guest  Login
Title:

Disease Modification in Multiple Sclerosis by Flupirtine-Results of a Randomized Placebo Controlled Phase II Trial.

Document type:
Journal Article; Article
Author(s):
Dörr, Jan; Wernecke, Klaus-Dieter; Würfel, Jens; Bellmann-Strobl, Judith; Siffrin, Volker; Sättler, Muriel B; Simons, Mikael; Linsa, Andreas; Tumani, Hayrettin; Paul, Friedemann
Abstract:
Central nervous system inflammation and neurodegeneration are the pathophysiological hallmarks of multiple sclerosis (MS). While inflammation can readily be targeted by current disease modifying drugs, neurodegeneration is by far less accessible to treatment. Based on suggested additional neuroprotective capacities of the orally available non-opioid and centrally acting analgesic drug flupirtine maleate we hypothesized that treatment with flupirtine maleate might be beneficial in MS patients. Th...     »
Journal title abbreviation:
Front Neurol
Year:
2018
Journal volume:
9
Pages contribution:
842
Fulltext / DOI:
doi:10.3389/fneur.2018.00842
Pubmed ID:
http://view.ncbi.nlm.nih.gov/pubmed/30356868
Print-ISSN:
1664-2295
TUM Institution:
Lehrstuhl für Zellbiologie des Nervensystems (Prof. Misgeld)
 BibTeX